RKRafaela Kramer

Rafaela Kramer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rafaela Kramer has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Carola Berking

    Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), CCC Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany

    4 shared publications
  • Michael Erdmann

    Department of Dermatology, University Hospital Erlangen, Erlangen, Germany

    3 shared publications
  • Elias A. T. Koch

    Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), CCC Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany

    2 shared publications
  • Markus Valentin Heppt

    Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany

    2 shared publications
  • Stefan Schliep

    Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), CCC Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany

    2 shared publications
  • Thomas Breakell

    Department of Dermatology, Uniklinikum Erlangen, Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany

    2 shared publications

Latest Publications

  • Open Access

    Eosinophilic, Polymorphic, and Pruritic Eruption After Pelvic Radiotherapy for Prostate Cancer

    by Bita Karimi, Carola Berking, Cornelia Erfurt-Berge, Rafaela Kramer, Stefan Schliep, Wiebke Sondermann, Elias A. T. Koch

    Eosinophilic, polymorphic, and pruritic eruption associated with radiotherapy (EPPER) is a rare and probably underrecognized cutaneous reaction to ionizing radiation with marked clinicopathological variability. We report a 59-year-old patient with prostate adenocarcinoma who developed a rapidly progressive, generalized pruritic eruption with tense bullae approximately two weeks after initiation of pelvic radiotherapy. The eruption began in the gluteal region and spread to the trunk and extremities, accompanied by shallow buccal erosions and mild systemic inflammation. Diagnostic evaluation showed no evidence of an autoimmune blistering disorder. Histopathology revealed an eosinophil-rich spongiotic dermatitis with vesiculobullous changes, supporting EPPER in the appropriate clinical context. With continued systemic and topical corticosteroid therapy, the eruption gradually resolved. Radiotherapy was temporarily interrupted but subsequently resumed and completed under corticosteroid treatment, with only a mild self-limited flare and no recurrent bullae. This case highlights the vesiculobullous spectrum of EPPER and underscores the importance of the temporal relationship to radiotherapy and close clinicopathological correlation for accurate diagnosis.

  • Open Access

    Management of Facial Immune Checkpoint Inhibitor-Induced Vitiligo with Topical Ruxolitinib: Quantitative Assessment Using a Semi-Automatic Tool

    by Thomas Breakell, Paolo Neri, Léonie A. N. Staats, Rafaela Kramer, Carola Berking, Michael Erdmann, Anke Hartmann

    Immune checkpoint inhibitors (ICIs) have substantially improved outcomes in advanced melanoma but are frequently linked to immune-related adverse events (irAEs). Vitiligo is a common cutaneous irAE and has been consistently associated with improved patient outcome, including prolonged progression-free and overall survival. It also represents significant visual stigma, particularly when the face is involved. Traditional treatment comprises topical steroids, calcineurin inhibitors, laser, and phototherapy which often have insufficient effects. Since 2023, the first approved drug for non-segmental vitiligo (NSV) with facial involvement, the topical Janus kinase inhibitor ruxolitinib, has been available. However, experience with its use in ICI-induced vitiligo remains limited. In this exploratory analysis, three patients who developed facial vitiligo following ICI therapy applied 1.5% ruxolitinib cream to affected facial areas twice daily. After six (two patients), and twelve months (one patient), extensive repigmentation was observed, quantified at 95.7%, 78.9%, and 99.1% using a novel semi-automatic tool. Quality-of-life questionnaires showed mean reductions of 57.6% (Vitiligo DLQI) and 68.2% (Vitiligo-specific Quality of Life) in disease burden. Treatment was associated with substantial repigmentation without observed side effects. Further evaluation in larger, prospective cohorts is warranted to better define treatment effects, clinical applicability, and long-term safety.

  • Top Cited Papers
    Open Access

    Ultraviolet Filters: Dissecting Current Facts and Myths

    by Thomas Breakell, Isabel Kowalski, Yannick Foerster, Rafaela Kramer, Michael Erdmann, Carola Berking, Markus V. Heppt

    Skin cancer is a global and increasingly prevalent issue, causing significant individual and economic damage. UV filters in sunscreens play a major role in mitigating the risks that solar ultraviolet ra-diation poses to the human organism. While empirically effective, multiple adverse effects of these compounds are discussed in the media and in scientific research. UV filters are blamed for the dis-ruption of endocrine processes and vitamin D synthesis, damaging effects on the environment, induction of acne and neurotoxic and carcinogenic effects. Some of these allegations are based on scientific facts while others are simply arbitrary. This is especially dangerous considering the risks of exposing unprotected skin to the sun. In summary, UV filters approved by the respective governing bodies are safe for human use and their proven skin cancer-preventing properties make them in-dispensable for sensible sun protection habits. Nonetheless, compounds like octocrylene and ben-zophenone-3 that are linked to the harming of marine ecosystems could be omitted from skin care regimens in favor of the myriad of non-toxic UV filters.


  • The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects

    by Carolin Ertl, Theresa Ruf, Dirk Mentzer, Mingzi Kong, Rafaela Kramer, Michael von Bergwelt-Baildon, Marion Subklewe, Dirk Tomsitz, Paolo A. Ascierto, Reinhard Dummer, et al.


  • Open Access

    Standardized Computer-Assisted Analysis of PRAME Immunoreactivity in Dysplastic Nevi and Superficial Spreading Melanomas

    by Elias A. T. Koch, Michael Erdmann, Carola Berking, Franklin Kiesewetter, Rafaela Kramer, Stefan Schliep, Markus V. Heppt

    PRAME (PReferentially expressed Antigen in MElanoma) is a cancer testis antigen that is frequently expressed in melanoma compared to benign melanocytic proliferations and nevi. However, the interpretation of the intensity and distribution of PRAME immunostaining is not standardized a lot, which makes interpretation difficult. PRAME-stained histological slides of superficial spreading melanomas (SSM) and dysplastic nevi (DN) were digitized and analyzed using the digital pathology and image platform QuPath. t-tests and ROC AUCs were performed with SPSS. A p-value of 0.8 was considered a good result. A cut-off score was defined in an evaluation cohort and subsequently analyzed in an independent validation cohort. In total, 81 PRAME-stained specimens were included. The evaluation cohort included 32 (50%) SSM and 32 (50%) DN, and the mean of PRAME-positive cells/mm2 for the entire lesion was 455.3 (SD 428.2) in SSM and 60.5 (SD 130.1; p < 0.001) in DN. The ROC AUC of PRAME-positive cells of the entire lesion was 0.866, and in the epidermis it was 0.901. The defined cut-off score to distinguish between DN and SSM was 97.67 cells/mm2. In the validation cohort, 16 out of 17 cases (94.1%) were correctly classified by the cut-off score. The computer-aided assessment of PRAME immunostaining is a useful tool in dermatopathology to distinguish between DN and SSM. Lesions with a moderate expression and indifferent morphologic features will remain a challenge for dermatopathologists.